Brown Lisle Cummings Inc. Has $547,000 Position in Zoetis Inc. (NYSE:ZTS)

Brown Lisle Cummings Inc. trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 23.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,800 shares of the company’s stock after selling 850 shares during the quarter. Brown Lisle Cummings Inc.’s holdings in Zoetis were worth $547,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. RFG Advisory LLC acquired a new stake in shares of Zoetis during the 1st quarter valued at $307,000. &PARTNERS acquired a new stake in shares of Zoetis during the first quarter valued at about $399,000. International Assets Investment Management LLC grew its holdings in shares of Zoetis by 13.2% during the first quarter. International Assets Investment Management LLC now owns 2,749 shares of the company’s stock worth $459,000 after purchasing an additional 320 shares during the last quarter. Global Assets Advisory LLC acquired a new position in shares of Zoetis in the first quarter valued at approximately $8,831,000. Finally, Harbor Investment Advisory LLC raised its holdings in Zoetis by 13.1% in the 1st quarter. Harbor Investment Advisory LLC now owns 6,599 shares of the company’s stock valued at $1,117,000 after buying an additional 764 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ZTS. Stifel Nicolaus upped their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. BTIG Research increased their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Piper Sandler lifted their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, JPMorgan Chase & Co. lifted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $221.44.

Zoetis Trading Up 1.2 %

Shares of ZTS stock opened at $193.28 on Monday. The company has a market cap of $87.57 billion, a P/E ratio of 37.82, a PEG ratio of 3.00 and a beta of 0.89. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The stock has a 50 day simple moving average of $188.98 and a two-hundred day simple moving average of $177.17. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. Zoetis’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.41 EPS. Research analysts forecast that Zoetis Inc. will post 5.83 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be paid a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.89%. Zoetis’s dividend payout ratio is presently 33.86%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.